Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Paliperidone Palmitate IM Injection Sites in Schizophrenia
NCT00073320Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2003
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, open-label trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Pharmacokinetic parameter estimates up to 64 days. Started Aug 2003; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00073320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073320.